New hope for rare blood vessel disorders: everolimus trial launches
NCT ID NCT07477548
First seen Mar 20, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This study tests the drug everolimus in 67 people with rare blood vessel growths or malformations that haven't responded to other treatments. The goal is to see if everolimus can shrink these growths or improve symptoms. Participants take the drug daily for at least 6 months, and doctors monitor their response with scans and blood tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR MALFORMATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.